Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMAHOVJ)

Drug Name
Crizanlizumab Drug Info
Synonyms SEG101
Indication
Disease Entry ICD 11 Status REF
Vaso-occlusive crisis BE2Y Approved [1]
Sickle-cell disorder 3A51 Phase 4 [2]
Cross-matching ID
TTD Drug ID
DMAHOVJ

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
P-selectin (SELP) TTE5VG0 LYAM3_HUMAN Inhibitor [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
P-selectin (SELP) DTT SELP 7.304 7.427 7.315 7.849
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Vaso-occlusive crisis
ICD Disease Classification BE2Y
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
P-selectin (SELP) DTT SELP 1.72E-04 1.23 0.86
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
2 ClinicalTrials.gov (NCT04662931) An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab in Sickle Cell Disease Patients. U.S. National Institutes of Health.
3 Crizanlizumab: First Approval. Drugs. 2020 Jan;80(1):79-84.